

REMARKS:

Replacement drawings are enclosed herewith as discussed above.

The specification has been amended to include the references to the sequence listing reference numbers as suggested by the examiner.


As discussed above, in preparation of the replacement drawings and amendments to the specification, it was noted that Figures 6A and 6B refer to G15-light and G15-heavy sequences which as discussed above did not appear in the originally filed sequence listing.

As the examiner can see, at this time the applicants have elected F26G18 monoclonal anti-SARS antibody. Accordingly, the claims have been restricted to F26G18 heavy and/or light chains.

The amendment of the claims to exclude certain subject matter is done without prejudice and the applicants reserve the rights to pursue these or similar claims, specifically, claims directed to other monoclonal antibodies or heavy or light chains thereof in one or more divisional, continuing and/or continuation in part applications.

Respectfully submitted

Jody Berry et al.

PER   
\_\_\_\_\_  
Michael R. Williams  
Registration No. 45333

April 16, 2009  
Enc.()

Winnipeg, Manitoba, Canada  
Telephone (204) 947-1429 - FAX (204) 942-5723